Why British urology should support RADICALS despite initial slow recruitment

References 

1. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. The Journal of Urology. 2009;181(March (3)):956–962
   • Abstract
   • Full Text
   • Full-Text PDF (553 KB)
   • CrossRef
2. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366(August (9485)):572–578
   • Abstract
   • Full Text
   • Full-Text PDF (111 KB)
   • CrossRef
3. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapyafter radical prostatectomy compared with radical prostatecomy alone in pT3 prostate cancer with postoperative undetectable prostate specific antigen: ARO 96-02/AUO AP 09/95. Journal of Clinical Oncology. 2009;(June (18)):2924–2930
4. Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo , et al. European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). European Journal of Cancer. 2005;41(November (17)):2662–2672